中华皮肤科杂志 ›› 2026, Vol. 59 ›› Issue (7): 671-674.doi: 10.35541/cjd.20250729

• 研究报道 • 上一篇    下一篇

司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察

魏瑾1    闫会文1    张建中2    伦文辉1   

  1. 1首都医科大学附属北京地坛医院皮肤性病科，北京  100015；2北京大学人民医院皮肤科，北京  100044
  • 收稿日期:2025-12-29 修回日期:2026-05-13 发布日期:2026-07-03
  • 通讯作者: 伦文辉 E-mail:lunwenhui@163.com

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases

Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹   

  1. ¹Department of Dermatology and Venereology, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China; ²Department of Dermatology, Peking University People's Hospital, Beijing 100044, China
  • Received:2025-12-29 Revised:2026-05-13 Published:2026-07-03
  • Contact: Lun Wenhui E-mail:lunwenhui@163.com

PDF

0

摘要： 【摘要】 目的 探讨司库奇尤单抗治疗合并人类免疫缺陷病毒（HIV）感染的中重度斑块状银屑病患者的临床疗效及安全性。方法 收集2021年10月至2024年12月期间在首都医科大学附属北京地坛医院皮肤性病科就诊的合并HIV感染的中重度斑块状银屑病患者，采用司库奇尤单抗注射液皮下注射150/300 mg治疗，第0 ~ 4周，每周注射1次，之后每4周注射1次；记录第0（基线）、4、12、24、48周银屑病皮损面积与严重程度指数（PASI）评分、皮肤病生活质量指数（DLQI），统计PASI评分较基线改善超过75%（PASI75）和90%（PASI90）的患者比例，记录不良反应的发生情况。结果 10例患者完成48周的治疗，均为男性，年龄27 ~ 44岁，治疗前PASI评分（18.4 ± 4.9）分。第4、12、24、48周时患者的PASI改善率（x ± s）分别为78.9% ± 11.1%、91.4% ± 7.5%、95.2% ± 4.2%、98.1% ± 2.1%，分别有7例、9例、10例、10例患者达PASI75，分别有1例、7例、8例、10例患者达 PASI90。同时DLQI评分也由治疗前的（21.6 ± 3.1）分降至48周时的（1.0 ± 0.9）分。司库奇尤单抗治疗期间，所有患者接受规律持续抗反转录病毒治疗，CD4+ T细胞计数保持稳定（＞200个/μl），HIV病毒载量均 < 50拷贝/ml。1例出现轻度不良事件（特应性皮炎），对症治疗后症状已缓解；未出现治疗中断或机会性感染。结论 司库奇尤单抗治疗对于接受抗病毒治疗且持续病毒学抑制的HIV阳性斑块状银屑病患者起效迅速，总体疗效显著，治疗依从性较好，未发现影响HIV病情的情况。

关键词: 银屑病, HIV感染, 司库奇尤单抗, 治疗, 疗效, 安全性

Abstract: 【Abstract】 Objective To evaluate the clinical efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by human immunodeficiency virus （HIV） infection. Methods Patients with moderate-to-severe plaque psoriasis complicated by HIV infection were enrolled from the Department of Dermatology and Venereology, Beijing Ditan Hospital, Capital Medical University from October 2021 to December 2024. All patients received subcutaneous injections of secukinumab at a dose of 150 or 300 mg once weekly from week 0 to 4, followed by every-4-week dosing thereafter. The Psoriasis Area and Severity Index （PASI） score and Dermatology Life Quality Index （DLQI） were assessed at weeks 0 （baseline）, 4, 12, 24, and 48. The proportions of patients achieving ≥ 75% and ≥ 90% improvements in PASI scores （PASI75, PASI90, respectively） from baseline were calculated, and adverse reactions were recorded. Results Ten patients completed the 48-week treatment, all of whom were males, aged 27 ? 44 years, with a baseline PASI score of 18.4 ± 4.9 points. At weeks 4, 12, 24, and 48, the PASI improvement rates （mean ± standard deviation） were 78.9% ± 11.1%, 91.4% ± 7.5%, 95.2% ± 4.2%, and 98.1% ± 2.1%, respectively; 7, 9, 10, and 10 patients achieved PASI75, and 1, 7, 8, and 10 patients achieved PASI90 at the above corresponding time points, respectively. Meanwhile, the DLQI score decreased from 21.6 ± 3.1 points at baseline to 1.0 ± 0.9 points at week 48. During treatment with secukinumab, all patients received regular and continuous antiretroviral therapy, with CD4? T-cell counts stable （> 200 cells/μl） and HIV viral loads consistently below 50 copies/ml. One patient experienced a mild adverse event （atopic dermatitis）, which resolved after symptomatic treatment; no treatment discontinuation or opportunistic infections occurred. Conclusions Secukinumab demonstrated rapid onset of action, significant overall efficacy, and favorable treatment adherence in HIV-positive patients with plaque psoriasis who were receiving antiretroviral therapy and maintained sustained virological suppression. Moreover, no adverse effects on HIV infection status were observed.

Key words: Psoriasis, HIV infections, Secukinumab, Therapy, Efficacy, Safety

引用本文

魏瑾 闫会文 张建中 伦文辉. 司库奇尤单抗治疗合并人类免疫缺陷病毒感染的中重度斑块状银屑病10例临床疗效观察[J]. 中华皮肤科杂志, 2026,59(7):671-674. doi:10.35541/cjd.20250729

Wei Jin¹, Yan Huiwen¹, Zhang Jianzhong², Lun Wenhui¹. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis complicated by HIV infection: a clinical observation of 10 cases[J]. Chinese Journal of Dermatology, 2026, 59(7): 671-674.doi:10.35541/cjd.20250729